Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

NCT05366829 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Hepatocellular
Liver Cell Carcinoma

Interventions

DRUG: Tislelizumab

Sponsor

Rutgers, The State University of New Jersey

Collaborators

[object Object]
[object Object]